TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23688162

Group type: EXPERIMENTAL
Intervention: 0.5% nifedipine cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Good moisturizer (control)
Number of subjects: 20
Study: 22850710

Group type: EXPERIMENTAL
Intervention: Transtibial (TT) group
Number of subjects: 76

Group type: COMPARATOR
Intervention: Anteromedial (AM) group
Number of subjects: 76
Study: 21173378

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by either surgery or chemoradiotherapy
Number of subjects: 47
Study: 17368645

Group type: EXPERIMENTAL
Intervention: Lactated Ringer solution
Number of subjects: 178

Group type: COMPARATOR
Intervention: Glucose-boosted saline solution (5% glucose)
Number of subjects: 178
Study: 16379581

Group type: EXPERIMENTAL
Intervention: Traxoprodil (CP-101,606) 72-hour infusion
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 11917251

Group type: EXPERIMENTAL
Intervention: Topical application of 1% aqueous extract of Fucus vesiculosus, applied twice daily for five weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9637644

Group type: EXPERIMENTAL
Intervention: 5 microg/kg oral clonidine (clonidine group, n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No clonidine (control group, n=25)
Number of subjects: 50
Study: 7527329

Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 0
Study: 2604057

Group type: EXPERIMENTAL
Intervention: Peripheral electrical stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 28421779

Group type: EXPERIMENTAL
Intervention: Oral glutamine (0.5 g/kg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (maltodextrin)
Number of subjects: 28
Study: 26329749

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg/day for 5 years
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Telbivudine after lamivudine 100 mg/day for 2 years
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Telbivudine treatment
Number of subjects: 57
Study: 23159787

Group type: EXPERIMENTAL
Intervention: Rhythmic music cueing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metronome cueing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Uncued baseline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Retest measures
Number of subjects: 30
Study: 21545506

Group type: EXPERIMENTAL
Intervention: 100 mg cyclosporin emulsion once daily (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 50 mg cyclosporin emulsion twice daily (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 40
Study: 18840643

Group type: EXPERIMENTAL
Intervention: High calcium intake (670-2003 mg/d)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Serum IGF-I concentration
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Other serum hormone levels
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Biomarkers of bone metabolism, habitual physical activity, habitual calcium intake, and physical fitness
Number of subjects: 31
Study: 16553019

Group type: EXPERIMENTAL
Intervention: Tiagabine 4 mg
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Tiagabine 6 mg
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Tiagabine 8 mg
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Tiagabine 2 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 15071278

Group type: EXPERIMENTAL
Intervention: Subclavian route of insertion
Number of subjects: 539
Study: 11128236

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 9188109

Group type: EXPERIMENTAL
Intervention: 0.2 mg.kg‐1 nasally
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 0.5 mg.kg‐1 rectally
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 0.2 mg.kg‐1 sublingually
Number of subjects: 47

Group type: COMPARATOR
Intervention: All groups (nasal, rectal, sublingual)
Number of subjects: 47
Study: 8430625

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study: 2964215

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.05-0.15 μg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diazepam (0.05-0.15 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 10
Study: 29846992

Group type: EXPERIMENTAL
Intervention: Baseline Adverse Electrical Remodeling (AER) measured by SAI QRST
Number of subjects: 961

Group type: COMPARATOR
Intervention: High SAI QRST (T3)
Number of subjects: 961

Group type: COMPARATOR
Intervention: Medium SAI QRST (T2)
Number of subjects: 961
Study: 26784973

Group type: EXPERIMENTAL
Intervention: Resveratrol 1.5 g daily for 6 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 28
Study: 25819604

Group type: EXPERIMENTAL
Intervention: Choice group (offered two selected vegetables)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No-choice group (offered one vegetable)
Number of subjects: 70
Study: 23731362

Group type: EXPERIMENTAL
Intervention: 1,200-mg oral-N-acetylcysteine (NAC) two times a day, starting 48 hours before and up to 72 hours after surgery
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 1,200-mg oral-N-acetylcysteine (NAC)
Number of subjects: 240
Study: 21986350

Group type: EXPERIMENTAL
Intervention: Individual education
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Group education
Number of subjects: 623

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 623
Study: 19995505

Group type: EXPERIMENTAL
Intervention: Helioseal Clear Chroma
Number of subjects: 31

Group type: COMPARATOR
Intervention: Delton FS(+)
Number of subjects: 31
Study: 17011327

Group type: EXPERIMENTAL
Intervention: Triptorelin 3.75 mg every 4 weeks (group 1)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Not treated (group 2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (age-matched normal volunteers)
Number of subjects: 62
Study: 15233305

Group type: EXPERIMENTAL
Intervention: Ofloxacin (O)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rifampicin (R)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isoniazid (H)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pyrazinamide (Z)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of drugs (O, R, H, Z)
Number of subjects: 12
Study: 11198725

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 12.5 mg
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo (demulcent lozenge without active drug)
Number of subjects: 301
Study: 9141578

Group type: EXPERIMENTAL
Intervention: Umbilical artery Doppler velocimetry
Number of subjects: 11375
Study: 8363681

Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg initial dose, repeat 100-200 mg at 2 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg bite and swallow every hour up to 20 mg total)
Number of subjects: 20
Study: 3540024

Group type: EXPERIMENTAL
Intervention: Metronidazole (1-week course)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30020962

Group type: EXPERIMENTAL
Intervention: Genome sequencing for expanded carrier screening reporting carrier results for 728 gene/condition pairs and results for 121 secondary findings.
Number of subjects: 277
Study: 27262966

Group type: EXPERIMENTAL
Intervention: Dissociated pulmonary vein activity after PVI
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pacing within the isolated PV
Number of subjects: 52

Group type: COMPARATOR
Intervention: Presence of AF prior to achieving PVI
Number of subjects: 52
Study: 24844271

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily for 24 weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo once daily for 24 weeks
Number of subjects: 240
Study: 23263426

Group type: EXPERIMENTAL
Intervention: Embrace
Number of subjects: 17

Group type: COMPARATOR
Intervention: Delton FS+
Number of subjects: 17
Study: 20122848

Group type: EXPERIMENTAL
Intervention: 40,000 IU vitamin D per week (group DD)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: 20,000 IU vitamin D per week (group DP)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Placebo (group PP)
Number of subjects: 437
Study: 18402717

Group type: EXPERIMENTAL
Intervention: Brimonidine purite 0.1% TID
Number of subjects: 40

Group type: COMPARATOR
Intervention: Brinzolamide 1% TID
Number of subjects: 40
Study: 16377943

Group type: EXPERIMENTAL
Intervention: Dominant hand
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Non-dominant hand
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both hands
Number of subjects: 30
Study: 12569373

Group type: EXPERIMENTAL
Intervention: CPT-11 + cisplatin (CPT-P)
Number of subjects: 398

Group type: COMPARATOR
Intervention: cisplatin + vindesine (VDS-P)
Number of subjects: 398

Group type: COMPARATOR
Intervention: CPT-11 alone (CPT)
Number of subjects: 398
Study: 10655908

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (2.5 micrograms kg‐1 min‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (Ketamine and Saline)
Number of subjects: 30
Study: 8542050

Group type: EXPERIMENTAL
Intervention: benazepril/hydrochlorothiazide, 20/25 mg
Number of subjects: 334

Group type: COMPARATOR
Intervention: benazepril, 20 mg
Number of subjects: 334

Group type: COMPARATOR
Intervention: hydrochlorothiazide, 25 mg
Number of subjects: 334

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 334
Study: 8263299

Group type: EXPERIMENTAL
Intervention: T.O.M. ointment containing oestradiol; applied before each breastfeeding from the 2nd to the 6th or 7th day of life.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ointment without oestradiol (non-treated group); applied before each breastfeeding from the 2nd to the 6th or 7th day of life.
Number of subjects: 80
Study: 3986167

Group type: EXPERIMENTAL
Intervention: Vaginal administration of 200 mg of progesterone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vaginal administration of 400 mg of progesterone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vaginal administration of 400 mg of progesterone (compared to placebo)
Number of subjects: 50
Study: 31899564

Group type: EXPERIMENTAL
Intervention: Counseling + Nicotine Replacement Therapy (C + NRT)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Counseling alone (C)
Number of subjects: 278
Study: 30115484

Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil PCA (40 μg bolus on demand with a 2 min lockout)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Intramuscular pethidine (100 mg every 4 h, up to 400 mg in 24 h)
Number of subjects: 401
Study: 27537587

Group type: EXPERIMENTAL
Intervention: propofol/remifentanil/DEX with loading dose (PRDw)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: propofol/remifentanil/DEX without loading dose (PRDo)
Number of subjects: 86

Group type: COMPARATOR
Intervention: propofol/remifentanil/Ringer solution (PRR)
Number of subjects: 86
Study: 24683594

Group type: EXPERIMENTAL
Intervention: FRC+intermediate adhesive resin+PFC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FRC+PFC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FRC+flowable resin+PFC
Number of subjects: 30
Study: 22710250

Group type: EXPERIMENTAL
Intervention: Recruitment maneuver (RM)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No recruitment maneuver (no-RM)
Number of subjects: 29
Study: 20434110

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg atracurium
Number of subjects: 79

Group type: COMPARATOR
Intervention: 5 mg succinylcholine
Number of subjects: 79

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 79
Study: 18390559

Group type: EXPERIMENTAL
Intervention: Double ejaculate
Number of subjects: 89

Group type: COMPARATOR
Intervention: Single ejaculate
Number of subjects: 89
Study: 16048928

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (3.375 g every 6 h)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Ertapenem (1 g once a day)
Number of subjects: 244
Study: 12090814

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 45
Study: 10321113

Group type: COMPARATOR
Intervention: Functional MR imaging in healthy volunteers
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Functional MR imaging in patients with brain tumours
Number of subjects: 28

Group type: COMPARATOR
Intervention: Functional MR imaging during left hand motion in healthy volunteers
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Functional MR imaging during motion of the affected hand in patients
Number of subjects: 28
Study: 8708718

Group type: COMPARATOR
Intervention: FUra/LV alone
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: FUra/LV/IFN alpha
Number of subjects: 260
Study: 1931703

Group type: EXPERIMENTAL
Intervention: MP/IFN (melphalan/prednisone plus natural IFN alpha)
Number of subjects: 220

Group type: COMPARATOR
Intervention: MP (melphalan/prednisone)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: MP/IFN
Number of subjects: 220

Group type: COMPARATOR
Intervention: MP
Number of subjects: 220
Study: 6338682

Group type: EXPERIMENTAL
Intervention: Noise exposure (100 dBA for 10 min)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Postsynaptic alpha‐adrenoceptor blockade (prazosin, 2 mg orally)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combined postsynaptic alpha‐ and non‐selective beta‐adrenoceptor blockade (labetalol, 200 mg orally)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Noise exposure
Number of subjects: 13
Study: 29268598

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (15 mL)
Number of subjects: 90
Study: 31471378

Group type: EXPERIMENTAL
Intervention: sCD14
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: WBC count
Number of subjects: 466
Study: 30041771

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) added to conventional treatment (aspirin 100mg/day with low molecular weight heparin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment (aspirin 100mg/day with low molecular weight heparin)
Number of subjects: 0
Study: 27282117

Group type: EXPERIMENTAL
Intervention: Interim Methadone (IM) initiated in jail
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Interim Methadone (IM) and patient navigation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual
Number of subjects: 300
Study: 23760038

Group type: EXPERIMENTAL
Intervention: Minimally invasive TKA (mini-midvastus approach)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional TKA (medial parapatellar approach)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups (Minimally invasive TKA and Conventional TKA)
Number of subjects: 66
Study: 22350859

Group type: EXPERIMENTAL
Intervention: Pictorial health warning labels (HWLs) with didactic textual forms
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Pictorial health warning labels (HWLs) with graphic imagery of diseased organs
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Pictorial health warning labels (HWLs) with testimonial narratives
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Pictorial health warning labels (HWLs) with didactic forms
Number of subjects: 1059
Study: 20799901

Group type: EXPERIMENTAL
Intervention: Nature arm (viewing nature scenes and listening to nature sounds)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: City arm (viewing city scenes and listening to city sounds)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard Care arm
Number of subjects: 120
Study: 17080429

Group type: EXPERIMENTAL
Intervention: Combination therapy (creatine monohydrate, coenzyme Q(10), and lipoic acid)
Number of subjects: 16
Study: 15604946

Group type: EXPERIMENTAL
Intervention: Automated 3-D quantification method
Number of subjects: 101

Group type: COMPARATOR
Intervention: Manual quantification method
Number of subjects: 101
Study: 12572768

Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 0
Study: 9458917

Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol (transdermal patch, approximately 0.1 mg/day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion (3% NaCl)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 6
Study: 9156817

Group type: EXPERIMENTAL
Intervention: Dextran‐40 based preservation solution (Dex‐PS)
Number of subjects: 174

Group type: COMPARATOR
Intervention: University of Wisconsin (UW) solution
Number of subjects: 174
Study: 2576685

Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 75

Group type: COMPARATOR
Intervention: d‐tubocurarine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 75
Study: 937570

Group type: EXPERIMENTAL
Intervention: Brief hospitalization (one week or less) with transitional day care available
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Brief hospitalization (one week or less) without day care
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard inpatient care (discharge at the therapist's discretion)
Number of subjects: 175
Study: 30601581

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 28601909

Group type: EXPERIMENTAL
Intervention: Microbial density (MD) in healthy eyes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pre-prosthesis MD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aerobic Gram-negative bacteria in retro-prosthesis samples
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Coagulase-negative staphylococci (excluding S. epidermidis) in retro-prosthesis samples
Number of subjects: 60
Study: 23768947

Group type: EXPERIMENTAL
Intervention: Existential Behavioural Therapy (EBT) with mindfulness training
Number of subjects: 130
Study: 23521205

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21806579

Group type: EXPERIMENTAL
Intervention: Cleansing cervical canal using sterile cotton swabs prior to embryo transfer
Number of subjects: 530

Group type: COMPARATOR
Intervention: Routine embryo transfer
Number of subjects: 530
Study: 20121952

Group type: EXPERIMENTAL
Intervention: 16-week supervised endurance exercise training (ET) program, walking and stationary cycling, three times per week for 30 to 40 minutes at moderate intensity
Number of subjects: 59

Group type: COMPARATOR
Intervention: Attention-control, nonexercise, usual care control group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 16-week supervised endurance exercise training (ET) program
Number of subjects: 59
Study: 16452132

Group type: EXPERIMENTAL
Intervention: New protocol for inter-physician information exchange
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard Belgian evaluation protocol
Number of subjects: 91
Study: 15605960

Group type: EXPERIMENTAL
Intervention: Warning about the imagination inflation effect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no warning)
Number of subjects: 0
Study: 11242723

Group type: EXPERIMENTAL
Intervention: Benzocaine 20% oral adhesive (Orabase-B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Benzocaine 20% gel (Hurricaine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EMLA 5% oral adhesive (EMLA 5% cream in Orabase Plain)
Number of subjects: 40
Study: 9140802

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nebivolol 10 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8274289

Group type: EXPERIMENTAL
Intervention: 0.1 M sphingosine in ethanol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.2 M sphingosine in ethanol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.0/0.2% isoquinoline in white vaseline/lanette wax cream
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0/10% tannic acid in lanette wax cream
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 100% coal tar
Number of subjects: 35

Group type: COMPARATOR
Intervention: 0.0/0.1/0.2 M sphingosine in ethanol
Number of subjects: 35
Study: 2884735

Group type: EXPERIMENTAL
Intervention: salazopyridazin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sulfasalazin
Number of subjects: 0

Group type: COMPARATOR
Intervention: d-Penicillamin
Number of subjects: 0
Study: 31907662

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Carbon nanoparticles (CN)
Number of subjects: 48
Study: 29176391

Group type: EXPERIMENTAL
Intervention: Average on-treatment SBP less than 142 mmHg (lowest tertile)
Number of subjects: 7998

Group type: EXPERIMENTAL
Intervention: Average SBP of 142 mmHg to less than 152 mmHg (middle tertile)
Number of subjects: 7998

Group type: COMPARATOR
Intervention: Average SBP of at least 152 mmHg (highest tertile and reference group)
Number of subjects: 7998
Study: 27214300

Group type: EXPERIMENTAL
Intervention: Lanreotide depot/autogel 120 mg
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 25959747

Group type: EXPERIMENTAL
Intervention: All routine vaccinations at birth (BCG/OPV/HBV)
Number of subjects: 120

Group type: COMPARATOR
Intervention: BCG delayed until after the study period (at day 5)
Number of subjects: 120

Group type: COMPARATOR
Intervention: All routine vaccinations delayed until after the study period
Number of subjects: 120
Study: 23478997

Group type: EXPERIMENTAL
Intervention: Low literacy
Number of subjects: 595